Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study

Autores/as

  • Jordan O'Dell KUMC
  • Caroline Mussatto
  • Rachel Chu
  • Mohammed Al-Sabbagh
  • Peter Timoney
  • Jason Sokol

DOI:

https://doi.org/10.17161/kjm.vol16.18940

Palabras clave:

Thyroid eye disease, teprotumumab, smoking

Resumen

Introduction. Smoking has been demonstrated to worsen the disease process and conventional treatment outcomes of thyroid eye disease. However, the effects of smoking on outcomes of thyroid eye disease treated with the novel therapeutic teprotumumab are currently unknown. Our study compares response to teprotumumab treatment between smokers and non-smokers with thyroid eye disease.  

Methods. We conducted a single-center, retrospective cohort study. Inclusion criteria were patients diagnosed with thyroid eye disease who had started or completed therapy with teprotumumab at the time of our data collection. Main outcome measures included reduction in clinical activity score, diplopia, and proptosis.

Results. We found that all smokers had type 2 thyroid eye disease prior to treatment and demonstrated less improvement in diplopia, proptosis, and overall clinical activity score compared to non-smokers with thyroid eye disease. There was no significant difference between smokers and non-smokers in baseline variables (sex, TSH, T4, T3, number of infusions completed). Data analysis revealed statistically significant difference in proptosis reduction between non-smokers and smokers.

Conclusions. Smoking is a modifiable risk factor which portends a worse response to treatment of thyroid eye disease with teprotumumab.

Métricas

File downloads
341
Mar 16 '23Mar 19 '23Mar 22 '23Mar 25 '23Mar 28 '23Mar 31 '23Apr 01 '23Apr 04 '23Apr 07 '23Apr 10 '23Apr 13 '238
|

Descargas

Publicado

2023-03-15

Número

Sección

Original Research

Cómo citar

O'Dell, J., Mussatto, C., Chu, R. ., Al-Sabbagh, M., Timoney, P. ., & Sokol, J. (2023). Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study. Kansas Journal of Medicine, 16(1), 62-64. https://doi.org/10.17161/kjm.vol16.18940